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Abstract
Background: The association between HIV viremia and non-AIDS-defining cancers (NADCs) is not well characterized.
Viremia may contribute directly or indirectly to cancer development and may have a differential impact on
various cancer types. Our objective was to characterize patterns of HIV viremia in a retrospective, urban,
clinical cohort (N = 320) of patients diagnosed with NADCs.
Findings: The most common NADC’s were lung (n = 60), prostate (n = 47), oropharyngeal (n = 32), liver (n = 29), and
anal cancer (n = 20) and Hodgkin lymphoma (n = 18). In the year before cancer diagnosis, 66 % of all patients were
virally suppressed. Patients with oropharyngeal (70 %) and prostate cancer (78 %) had a higher proportion of visits with
suppressed viral loads. Patients diagnosed with anal cancer and Hodgkin lymphoma were infrequently virally suppressed
and more frequently had viral loads ≥5 log10 copies/ml in the ten years prior to cancer diagnosis.
Conclusions: In this cohort of HIV-infected patients diagnosed with NADCs, there were important differences in the
patterns and levels of viremia between the different NADCs in the ten years prior to cancer diagnosis. Patients with anal
cancer and Hodgkin lymphoma had the highest proportion of high level viremia in the ten years before cancer and the
lowest frequency of viral load suppression at cancer diagnosis.
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Introduction
Cancer risk is markedly increased in HIV-infected in-
dividuals compared to the general population, and it
has become a frequent cause of morbidity and mor-
tality in this population. Multiple factors contribute
to the increased risk of both AIDS-defining cancers
(ADCs) and non-AIDS-defining cancers (NADCs), in-
cluding viremia, immune deficiency, oncogenic virus
co-infection (e.g. hepatitis B/C), behavioral carcinogen
exposures (e.g. alcohol and tobacco), aging, and pos-
sibly antiretroviral therapy (ART) [1–8].
HIV viremia may contribute directly to develop-
ment of ADCs, but for NADCs, the impact is not as
well characterized and may be indirect [2, 7, 9].
Viremia as a risk factor for malignancies has been
measured in various ways, including as duration of
high-level circulating virus (i.e., viral load (VL) ≥5
log10) [10], peak VL [11], current or time-lagged
nonsuppressed VL [2], and cumulative viremia (i.e.
approximate area under the curve) [3, 9], and ap-
pears to play a fundamental role in the development
of non-Hodgkin lymphoma (NHL) [2, 3, 10]. How-
ever, the actual mechanism by which circulating virus
contributes to lymphomagenesis is not yet known,
and the association and oncogenic mechanisms be-
tween HIV viremia and NADCs is understudied.
The purpose of this retrospective cohort study was to
characterize patterns of HIV viremia and viral suppres-
sion in the ten years preceding NADC diagnosis and to
compare these factors among the six most common
NADCs (Hodgkin lymphoma and oropharyngeal, anal,
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liver, lung, and prostate cancer) and to ADCs in a
diverse, urban clinic population.
Methods
Medical records of all HIV-infected individuals diag-
nosed with cancer in the University of Maryland
Medical System and Baltimore Veterans Affairs Med-
ical Center from January 2000 to December 2011
were reviewed. Data abstraction methods have been
previously described [12]. Cancer diagnoses were
confirmed by pathology and clinician reports and
were categorized as ADCs (Kaposi sarcoma, invasive
cervical cancer, and NHL) or NADCs (all other can-
cers except the three ADCs). The most common
NADCs were further divided into infection-related
(anal and liver cancer and Hodgkin lymphoma),
infection-unrelated (lung and prostate cancer), and
mixed (oropharyngeal cancer) [13]. Although oropha-
ryngeal cancers include a mixture of human papillo-
mavirus (HPV)-related and HPV-unrelated subtypes
[14], data on HPV DNA tissue testing or specific
anatomical subsites were not available. Institutional
Review Boards at each site approved the protocol.
All patients with ≥1 HIV VL measurement in the
ten years prior to cancer diagnosis were included in
this analysis. Measurements below the level of detec-
tion were assumed to be 1 log10. HIV suppression
was defined as an HIV RNA VL ≤400 copies/ml
(assays over time had varying detection limits). HIV
duration was time from HIV diagnosis to cancer
diagnosis.
Characteristics of patients are described for NADCs
and ADCs overall and for the six most common
NADCs, along with the proportion of clinical visits
before cancer diagnosis with viral suppression. Cat-
egorical variables were compared using chi square,
and continuous variables were compared using Wil-
coxon rank sum or student’s t test. Levels of viremia
(log10) in the 10 years preceding diagnosis are plotted
with a fitted linear trend line to examine differences
across time. Data analysis was performed using SAS
version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
There were 320 patients diagnosed with NADCs and
105 with ADCs. Characteristics of the patients are
shown in Table 1. The median age at NADC diagno-
sis was 54 (IQR: 48-59) years, and 68 % of NADCs
were in patients older than 50 years compared to
76 % of ADCs in patients 50 years or younger. The
median number of VL measurements per NADC
patient was 12 (IQR: 3-23). The most common
NADC’s in this population were lung (n = 60), pros-
tate (n = 47), oropharyngeal (n = 32), liver (n = 29), and
anal cancer (n = 20) and Hodgkin lymphoma (n = 18)
(Appendix).
In the year preceding cancer diagnosis, 66 % of all
patients with NADCs were virally suppressed com-
pared to only 24 % of patients with ADCs (Table 2).
Patients with oropharyngeal (70 %) and prostate can-
cer (78 %) had higher proportions of visits with sup-
pressed VL in the same time frame, while patients
with Hodgkin lymphoma (56 %) and anal cancer
(59 %) had lower frequencies of suppression prior to
cancer diagnosis. There was significant variability in
the proportion of VL suppression at 5-6, 7-8, and 9-
10 years before cancer diagnosis (Table 2). Patients
with Hodgkin lymphoma had a low proportion of
visits with viral suppression before cancer onset
(20 % at 3-4 years, 0 % at 5-6 years, 8 % at 7-8
years, and 0 % at 9-10 years). Overall 60 % of all
visits in NADC patients in the 10 years before cancer
diagnosis had suppressed VL.
The linear pattern of the individual log10 VL mea-
surements across time before cancer diagnosis for
the six NADCs is shown in Fig. 1a. The slope of
viremia curves for both Hodgkin lymphoma and anal
cancer were negative, while curves for the other four
NADCs were comparatively flat. Figure 1b shows the
pattern of VL across time for NADCs compared to
ADCs. When further examining the level of VL
among all patients with NADCs, only 6.6 % of visits
in the ten years before diagnosis had very high VL
(e.g. log10 VL ≥5). Patients with anal cancer (19.4 %)
and Hodgkin lymphoma (17.5 %) had the highest fre-
quency of ≥5 log10 VL measurements, while those
with prostate (2.7 %), liver (3.6 %), lung (5.1 %), and
oropharyngeal (6.9 %) cancers had the fewest.
Discussion
In this urban cohort of HIV-infected patients diag-
nosed with cancer, there were important differences
in the patterns of viral suppression and levels of
viremia between those with ADCs and NADCs and
among the different NADCs in the ten years prior to
cancer diagnosis. In general, patients with NADCs
had a high frequency of VL suppression and rarely
had high level viremia prior to cancer diagnosis.
Comparing the six most common NADCs, patients
with anal cancer and Hodgkin lymphoma had the
highest proportion of high level viremia in the ten
years before cancer and the lowest frequency of VL
suppression at cancer diagnosis. Conversely, patients
with prostate cancer had the highest frequency of VL
suppression at cancer diagnosis and the lowest fre-
quency of high level viremia prior to cancer diagnosis.
These differing patterns of viremia suggest that cer-
tain infection-related NADCs (anal cancer and
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Table 1 Demographic and clinical characteristics of patients diagnosed with ADCs and NADCs
All ADCs All NADCs P value* Infection-related NADC Infection-unrelated
NADC
Mixeda
(n = 105) (n = 320)
Hodgkin Anal Liver Lung Prostate Oral
(n = 18) (n = 20) (n = 29) (n = 60) (n = 47) (n = 32)
Characteristics N (%) or
Median (IQR)
N (%) or Median (IQR)
Year of diagnosis
2000-2005 39 (37 %) 90 (28 %) 7 (39 %) 4 (20 %) 5 (17 %) 19 (32 %) 8 (17 %) 9 (28 %)
2006-2011 66 (63 %) 230 (72 %) 0.08 11 (61 %) 16 (80 %) 24 (83 %) 41 (68 %) 39 (83 %) 23 (72 %)
Age (years)
≤50 years 80 (76 %) 101 (32 %) 13 (72 %) 15 (75 %) 5 (17 %) 17 (28 %) 1 (2 %) 10 (31 %)
>50 years 25 (24 % 219 (68 %) <0.01 5 (28 %) 5 (25 %) 24 (83 %) 43 (72 %) 46 (98 %) 22 (69 %)
Male 81 (77 %) 255 (80 %) 0.58 14 (78 %) 19 (95 %) 29 (100 %) 52 (87 %) 47 (100 %) 23 (72 %)
Black race 89 (85 %) 280 (88 %) 0.04 17 (94 %) 18 (90 %) 24 (83 %) 55 (92 %) 44 (94 %) 31 (97 %)
Smoking
Current/Former 75 (71 %) 284 (89 %) 15 (83 %) 18 (90 %) 27 (93 %) 59 (98 %) 43 (91 %) 30 (94 %)
Never 30 (29 %) 36 (11 %) <0.01 3 (17 %) 2 (10 %) 2 (7 %) 1 (2 %) 4 (9 %) 2 (6 %)
Alcohol
Current/Former 37 (35 %) 188 (59 %) 9 (50 %) 6 (30 %) 26 (90 %) 40 (67 %) 33 (70 %) 26 (81 %)
Never 68 (65 %) 132 (41 %) <0.01 9 (50 %) 14 (70 %) 3 (10 %) 20 (33 %) 14 (30 %) 6 (19 %)
Injection drug use
Current/Former 43 (41 %) 165 (52 %) 7 (39 %) 8 (40 %) 20 (69 %) 32 (53 %) 19 (40 %) 21 (66 %)
Never 62 (59 %) 155 (48 %) 0.06 11 (61 %) 12 (60 %) 9 (31 %) 28 (47 %) 28 (60 %) 11 (34 %)
HIV Transmission
IDU 38 (36 %) 145 (45 %) 4 22 %) 6 (30 %) 18 (62 %) 28 (47 %) 19 (40 %) 22 (69 %)
Heterosexual 33 (31 %) 104 (33 %) 7 (39 %) 1 (5 %) 5 (17 %) 24 (40 %) 19 (40 %) 9 (28 %)
MSM 29 (28 %) 50 (16 %) 6 (33 %) 11 (55 %) 5 (17 %) 6 (10 %) 5 (11 %) 0 (0 %)
Transfusion 0 (0 %) 3 (1 %) 0 (0 %) 0 (0 %) 0 (0 %) 1 (2 %) 0 (0 %) 0 (0 %)
Unknown 5 (5 %) 18 (6 %) 0.07 1 (6 %) 2 (10 %) 1 (3 %) 1 (2 %) 4 (9 %) 1 (3 %)
Hepatitis C 42 (40 %) 166 (52 %) 0.03 5 (28 %) 9 (45 %) 22 (76 %) 28 (47 %) 27 (57 %) 22 (69 %)
HIV duration
(years)b
6.4 (1.9-12.2) 11.0 (5.6, 15.3) <0.01 6.3 (4.1, 14.2) 14.0 (8.4, 16.4) 13.6 (7.0, 15.0) 11.4 (5.6, 15.7) 10.8 (5.3, 14.7) 14.2 (7.8, 19.0)
CD4 cell countc
≤200 37 (38 %) 197 (68 %) 6 (33 %) 9 (53 %) 17 (68 %) 32 (60 %) 36 (80 %) 15 (56 %)
>200 48 (50 %) 65 (22 %) 10 (56 %) 6 (35 %) 5 (20 %) 15 (28 %) 4 (9 %) 8 (30 %)
Unknown 12 (12 %) 28 (10 %) <0.01 2 (11 %) 2 (12 %) 3 (12 %) 6 (11 %) 5 (11 %) 4 (15 %)
Average no. of HIV
RNA VL per patient
6 15 <0.01 10 15 14 13 21 15
Log10 VL
(copies/ml)c
4.5 (2.9-5.1) 1.7 (1.0, 3.9) <0.01 3.0 (1.0, 4.4) 1.0 (1.0, 2.0) 1.9 (1.0, 4.4) 2.9 (1.0, 4.4) 1.0 (1.0, 2.2) 1.0 (1.0, 3.7)
HIV RNA VL
suppression ≤400c
23 (34 %) 182 (63 %) <0.01 9 (50 %) 13 (76 %) 13 (52 %) 25 (47 %) 34 (76 %) 17 (63 %)
ART at diagnosis 34 (32 %) 187 (58 %) <0.01 6 (33 %) 15 (75 %) 13 (45 %) 31 (52 %) 39 (83 %) 17 (53 %)
*P value is for comparison of ADCs vs. NADCs
aOropharyngeal cancers typically include both human papillomavirus-related and -unrelated cancers
bMissing HIV duration data: NADC's (2), Lung (1)
cN = 290 NADC's with measurements taken within one year before cancer diagnosis. Missing data by cancer individual cancers: Hodgkin (0), Anal (3), Liver (4),
Lung (7), Prostate (2), Oral (5)
ADCs AIDS-defining cancers, ART antiretroviral therapy, IDU injection drug use, NADCs non-AIDS-defining cancers, VL viral load
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Hodgkin lymphoma) may be more appropriately cate-
gorized with ADCs.
Consistent with earlier studies [2, 7], the majority
of NADCs in this cohort occurred in patients who
were virally suppressed, raising the possibility that
other mechanisms associated with HIV pathogenesis
may account for the increased incidence of some
NADCs. HIV-related immune activation, chronic in-
flammation, and immunodeficiency likely also play a
role in the development of many non-viral NADCs
[15]. The high prevalence of certain chronic viral in-
fections (e.g. hepatitis B/C) [4] and behavioral carcin-
ogens (such as smoking) [5] in the HIV-infected
population also contribute to the increased NADC
risk. Determining the etiologic role and attributable
risk fraction of these different factors remains a crit-
ical area of future research.
Compared to the four other NADCs studied, both
anal cancer and Hodgkin lymphoma had a high fre-
quency of visits with ≥5 log10 VL in the ten years
preceding cancer diagnosis and were also less fre-
quently virologically suppressed at the time of cancer
diagnosis. This finding is consistent with prior work
showing that cumulative HIV viremia was associated
with development of Hodgkin lymphoma and anal
cancer but not hepatocellular cancer [9]. Both anal
cancer and Hodgkin lymphoma are etiologically asso-
ciated with co-infecting oncogenic viruses (HPV and
Epstein Barr virus, respectively), and the co-existence
of persistent, high level circulating HIV viremia with
associated immunosuppression impairs the ability to
control and clear these viral co-infections [16]. HIV-
infected patients are also more likely to have anal
HPV infections, to have multiple, concurrent HPV
infections, and to carry high-risk, oncogenic HPV
subtypes [17]. These factors likely combine to in-
crease the risk for these particular cancers in the
HIV-infected population [13]. The results from this
study support previous work suggesting that virally
associated NADCs like anal cancer and Hodgkin
lymphoma may behave differently than typical non-
virally associated NADCs and more like an ADC,
with HIV itself as a contributory risk factor. Con-
tinuing to categorize cancers in HIV-infected patients
into the dichotomy of ADCs and NADCs may no
longer be supported by emerging biological and epi-
demiological data.
A strength of this study is the diverse clinical co-
hort of urban, HIV-infected patients with a high
prevalence of African-Americans, injection drug use
and hepatitis C virus co-infection, and smoking,
which is underrepresented in the literature. Most
prior work is from geographic areas or populations
with a high proportion of white race and male-to-
male sexual contact as the predominant HIV risk fac-
tor [13, 18]. As the study population consists largely
of inner city African-Americans of low socioeco-
nomic status, the results may not be generalizable to
all HIV-infected patients in other settings. Addition-
ally, the study inferences are limited by the retro-
spective and clinical nature of the data – VL
measures were not taken at standard intervals, al-
though reflecting the true nature of clinically ob-
served patterns of HIV viremia. Patients with certain
Table 2 All NADCs and the six most common individual NADCs: percent (N) of visits with viral suppression (HIV RNA viral load ≤400
copies/ml) before cancer onset
Cancer Within 1 year of
onset
Within 2 years of
onset
3-4 years prior to
onset
5-6 years prior to
onset
7-8 years prior to
onset
9-10 years prior to
onset
All ADCs 24 % (45) 18 % (12) 30 % (45) 41 % (41) 43 % (18) 38 % (11)
All NADCs 66 % (577) 61 % (429) 61 % (681) 56 % (468) 55 % (317) 65 % (220)
Infection related
Hodgkin 64 % (30) 48 % (23) 20 % (10) 0 % (0)a 8 % (1) 0 % (0)b
Anal 65 % (42) 53 % (28) 41 % (39) 20 % (11) 53 % (10) 40 % (2)
Liver 66 % (42) 64 % (28) 64 % (47) 68 % (49) 74 % (49) 65 % (26)
Infection unrelated
Lung 51 % (80) 50 % (66) 60 % (107) 62 % (78) 46 % (33) 44 % (27)
Prostate 79 % (118) 76 % (91) 71 % (154) 56 % (106) 49 % (74) 66 % (52)
Mixed
Oral 71 % (52) 69 % (43) 74 % (105) 71 % (61) 55 % (35) 50 % (17)
aThere were 0 visits with viral suppression out of 22
bThere were 0 visits with viral suppression out of 3
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NADCs had more frequent VL measures than others,
possibly implying that viremia could be a surrogate
for poor engagement in HIV care and higher rates of
high-risk behaviors. We also did not have access to a
non-cancer comparison group or comprehensive data
on traditional cancer risk factors, limiting the ability
to make more direct conclusions about the association of
viremia with cancer development and diagnosis. Lastly,
differences in ART utilization and efficacy may also have
contributed to differences in viremia among the various
groups.
In conclusion, we found that patients with NADCs
largely had suppressed VL at cancer diagnosis. Simi-
lar to ADCs, those with anal cancer and Hodgkin
lymphoma were less frequently virally suppressed in
the years preceding their cancer diagnosis than pa-
tients with prostate, lung, liver, or oropharyngeal
cancers. As NADCs continue to increase as a cause
of non-AIDS-related morbidity and mortality despite
viral suppression, further research should investigate
the role of circulating viremia in the pathogenesis of
these cancers.
Fig. 1 Patterns of log10 HIV RNA viral load prior to cancer diagnosis for the six most common NADCs (a) and for NADCs versus ADCs (b)
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load..
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DJR, AFR, RRR conceived and designed the study; DJR acquired the data; AFR
analyzed the data; DJR, AFR, RRR interpreted the analysis; DJR drafted the
manuscript; DJR, AFR, RRR all contributed to revisions. All authors approved
the final version of the manuscript. DJR had full access to all the data in the
study and takes responsibility for the integrity of the data and the accuracy
of the data analysis.
Acknowledgements
At the time of the study, DJR was supported by a Paul Calabresi Clinical
Oncology Training Program award (K12 CA126849), and AFR was supported,
in part, through a 2015 developmental grant from the Johns Hopkins
University Center for AIDS Research, an NIH funded program (P30AI094189).
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Author details
1Institute of Human Virology and Division of Infectious Diseases, University of
Maryland School of Medicine, Baltimore, MD, USA. 2Department of
Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
MD, USA. 3Institute of Human Virology and Division of Infectious Diseases,
University of Maryland School of Medicine, Program in Oncology, University
of Maryland Marlene and Stewart Greenebaum Cancer Center, 725 W.
Lombard St., N552, Baltimore, MD 21201, USA.
Received: 2 June 2015 Accepted: 11 September 2015
References
1. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect
of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk
of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
Lancet Oncol. 2009;10(12):1152–9. doi:10.1016/S1470-2045(09)70282-7.
2. Bruyand M, Thiebaut R, Lawson-Ayayi S, Joly P, Sasco AJ, Mercie P, et al.
Role of uncontrolled HIV RNA level and immunodeficiency in the
occurrence of malignancy in HIV-infected patients during the combination
antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS)
CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49(7):1109–16. doi:10.1086/
605594.
3. Zoufaly A, Stellbrink HJ, Heiden MA, Kollan C, Hoffmann C, van Lunzen J,
et al. Cumulative HIV viremia during highly active antiretroviral therapy is a
strong predictor of AIDS-related lymphoma. J Infect Dis. 2009;200(1):79–87.
doi:10.1086/599313.
4. Vallet-Pichard A, Pol S. Hepatitis viruses and human immunodeficiency virus
co-infection: pathogenesis and treatment. J Hepatol. 2004;41(1):156–66.
doi:10.1016/j.jhep.2004.05.001.
5. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al.
Cancer risk in the Swiss HIV Cohort Study: associations with
immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl
Cancer Inst. 2005;97(6):425–32. doi:10.1093/jnci/dji072.
6. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, et al.
Incidence and risk factors for the occurrence of non-AIDS-defining cancers
among human immunodeficiency virus-infected individuals. Cancer.
2005;104(7):1505–11. doi:10.1002/cncr.21334.
7. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel
RV, et al. Trends in the incidence of cancers among HIV-infected persons
and the impact of antiretroviral therapy: a 20-year cohort study. AIDS.
2009;23(1):41–50. doi:10.1097/QAD.0b013e328317cc2d.
8. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al.
Highly active antiretroviral therapy and the incidence of non-AIDS-defining
cancers in people with HIV infection. J Clin Oncol. 2009;27(6):884–90.
doi:10.1200/JCO.2008.19.6626.
9. Kowalkowski MA, Day RS, Du XL, Chan W, Chiao EY. Cumulative HIV viremia
and non-AIDS-defining malignancies among a sample of HIV-infected male
veterans. J Acquir Immune Defic Syndr. 2014;67(2):204–11. doi:10.1097/QAI.
0000000000000289.
10. Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic
predictors of AIDS-related non-hodgkin lymphoma in the highly active
antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54(1):78–84.
doi:10.1097/01.qai.0000371677.48743.8d.
11. Achenbach CJ, Buchanan AL, Cole SR, Hou L, Mugavero MJ, Crane HM, et al.
HIV viremia and incidence of non-Hodgkin lymphoma in patients
successfully treated with antiretroviral therapy. Clin Infect Dis.
2014;58(11):1599–606. doi:10.1093/cid/ciu076.
12. Riedel DJ, Mwangi EI, Fantry LE, Alexander C, Hossain MB, Pauza CD, et al.
High cancer-related mortality in an urban, predominantly African-American,
HIV-infected population. AIDS. 2013;27(7):1109–17. doi:10.1097/QAD.
0b013e32835dc068.
13. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV
infection and the risk of cancers with and without a known infectious
cause. AIDS. 2009;23(17):2337–45. doi:10.1097/QAD.0b013e3283319184.
14. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for
human papillomavirus-related and -unrelated oral squamous cell
Table 3 Number and distribution of non-AIDS-defining cancers
Cancer type N (%)
Lung 60 (14.1 %)
Prostate 47 (11.1 %)
Oral cavity and oropharynx 32 (7.5 %)
Liver/bile duct 29 (6.8 %)
Anal 20 (4.7 %)
Hodgkin lymphoma 18 (4.2 %)
Non-melanoma skin 16 (3.8 %)
Kidney 14 (3.3 %)
Breast 14 (3.3 %)
Intestine 13 (3.1 %)
Acute myeloid leukemia 7 (1.7 %)
Pancreas 7 (1.7 %)
Penis 7 (1.7 %)
Unknown primary 7 (1.7 %)
Bladder 5 (1.2 %)
Vulvar/vaginal 4 (0.9 %)
Ovary 3 (0.7 %)
Multiple myeloma 2 (0.5 %)
Castleman disease 1 (0.2 %)
Melanoma 1 (0.2 %)
Other leukemia 1 (0.2 %)
Stomach 1 (0.2 %)
Sarcoma 1 (0.2 %)
Testicular 1 (0.2 %)
Thyroid 1 (0.2 %)
Others 8 (1.9 %)
Riedel et al. Infectious Agents and Cancer  (2015) 10:38 Page 6 of 7
carcinomas in the United States. J Clin Oncol. 2008;26(4):612–9.
doi:10.1200/JCO.2007.14.1713.
15. Borges AH, Dubrow R, Silverberg MJ. Factors contributing to risk for cancer
among HIV-infected individuals, and evidence that earlier combination
antiretroviral therapy will alter this risk. Curr Opin HIV AIDS. 2013.
doi:10.1097/COH.0000000000000025.
16. Engels EA. Non-AIDS-defining malignancies in HIV-infected persons:
etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS.
2009;23(8):875–85. doi:10.1097/QAD.0b013e328329216a.
17. Tong WW, Hillman RJ, Kelleher AD, Grulich AE, Carr A. Anal intraepithelial
neoplasia and squamous cell carcinoma in HIV-infected adults. HIV Med.
2014;15(2):65–76. doi:10.1111/hiv.12080.
18. Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ,
et al. Mortality after cancer diagnosis in HIV-infected individuals treated
with antiretroviral therapy. AIDS. 2011;25(5):691–700. doi:10.1097/QAD.
0b013e3283437f77.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Riedel et al. Infectious Agents and Cancer  (2015) 10:38 Page 7 of 7
